CAS: 1028486-01-2; 4-((9-Chloro-7-(2-Fluoro-6-Methoxyphenyl)-5H-Benzo[c]Pyrimido[4,5-E]Azepin-2-yl)Amino)-2-Methoxybenzoic Acid

上下游产品

CAS号869367-33-9 (1E,4E)-8-chlor... | CAS号869365-97-9 (5-氯-2-碘苯基)(2,6... | CAS号28910-83-0 2-氨基-5-氯-2,6-二氟二苯甲酮 | CAS号1233025-91-6 (5-氯-2-碘苯基)(2-氟... | CAS号27492-84-8 2-甲氧基-4-氨基苯甲酸甲酯 | CAS号869366-70-1 TERT-BUTYL (3-(...

在 盐酸,Potassium Carbonate体系中,用 甲醇,水 用作溶剂,化学反应 4.0H,反应生成4-[[9-氯-7-(2-氟-6-甲氧基苯基)-5H-嘧啶并[5,4-D][2]苯并氮杂卓-2-基]氨基]-2-甲氧基苯甲酸
参考文献:具有aurora激酶降解活性的小分子及其制备 方法和应用
标题:具有aurora激酶降解活性的小分子及其制备 方法和应用
摘要:本发明公开了具有aurora激酶降解活性的小分子及其制备方法和应用.发明人运用crbn,Ciap和vhl三种e3泛素连接酶招募配体与已知的aurora‑a抑制剂mln8237,通过自有的linker设计技术,得到12种基于protac技术的aurora‑a蛋白降解剂.发明人通过western Blot实验证实这一类aurora‑a降解剂对aurora‑a的降解效果.Cck8细胞增殖实验及平板克隆形成实验证明这一类aurora‑a降解剂可以有效抑制细胞增殖及克隆形成.Spr实验证明这一类aurora‑a降解剂与aurora‑a蛋白直接结合.

专利信息

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:US-2023192681-A1
优先权日:2019-11-14
标 题 :Improved synthesis of kras g12c inhibitor compound

专利号:US-2017107577-A1
优先权日:2014-03-11
标题:Determining Cancer Aggressiveness, Prognosis and Responsiveness to Treatment
发明人：AL-EJEH FARES
权利人:THE COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES
摘要:The invention provides methods of determining the aggressiveness, prognosis and response to therapy for particular cancers, which include comparing the expression levels of one or a plurality of differentially expressed genes from one or more 5 functional metagenes, including a Carbohydrate/Lipid Metabolism metagene, a Cell Signalling metagene, a Cellular Development metagene, a Cellular Growth metagene, a Chromosome Segregation metagene, a DNA Replication/Recombination metagene, an Immune system metagene, a Metabolic Disease metagene, a Nucleic Acid Metabolism metagene, a Post-Translational Modification metagene, a Protein 10 Synthesis/Modification metagene and a Multiple Networks metagene. The method disclosed herein may be particularly suitable as a companion diagnostic for cancer therapies.

专利号:US-2022143183-A1
优先权日:2019-02-23
标题:Photoswitchable protacs and synthesis and uses thereof
发明人：TRAUNER DIRK; REYNDERS MARTIN; MATSUURA BRYAN; BEROUTI MARLEEN; PAGANO MICHELE
权利人:UNIV NEW YORK
摘要:Provided are compounds, which may be referred to as PHOTACs (photoswitchable proteolysis targeting chimeras), and compositions, kits, and methods of making and using PHOTACs. PHOTACs have one or more E3 ligase ligand(s), one or more photoswitchable group(s), optionally, one or more linker(s), and one or more ligand(s) for a target protein. PHOTACs may be suitable for use in methods to treat diseases, such as, for example, cancer. PHOTACs may also be suitable for use in methods to induce selective degradation of a target protein.

专利号:US-11299491-B2
优先权日:2018-11-16
标 题:Synthesis of key intermediate of KRAS G12C inhibitor compound